BIOPHYTIS SA ADS overview

IND to be filed with the FDA in the coming weeks PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical study in obesity. This Scientific Advisory Board will be composed...

Biophytis / Key word(s): Miscellaneous Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity 18-Apr-2024 / 07:02 CET/CEST Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity IND to be filed with the FDA in the coming weeks Paris (France) and Cambridge (Massachusetts, USA), April 18, 2024 – 07:00am CET – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a...

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, publishes today its financial results for the year ended December 31, 2023, and provides an update on the progress of its various programmes. "In 2023, despite a particularly difficult financial environment for the biotech sector, we...

Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces that it is launching a new clinical development program named OBA, with BIO101 (20-hydroxyecdysone) as...

Biophytis / Key word(s): Annual Results Biophytis announces its 2023 financial results and provides an update on its business activities 08-Apr-2024 / 23:04 CET/CEST Biophytis announces its 2023 financial results and provides an update on its business activities Paris (France) and Cambridge (Massachusetts, USA), April 08, 2024 – 11:00pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in...

Biophytis / Key word(s): Annual Results Biophytis announces its 2023 financial results and provides an update on its business activities 08-Apr-2024 / 23:01 CET/CEST Biophytis announces its 2023 financial results and provides an update on its business activities Paris (France) and Cambridge (Massachusetts, USA), April 08, 2024 – 11:00pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in...

Biophytis / Key word(s): Miscellaneous Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) 08-Apr-2024 / 23:00 CET/CEST Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 Paris (France) and Cambridge (Massachusetts, USA), April 08, 2024 – 11:00pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth...

All resolutions presented by the Company have been adopted PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 4, 2024 / Biophytis SA (NASDAQ CM BPTS),(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the...